Table 3.
Clinical characteristics of breast cancer patients and healthy controls of the validation cohort.
| Clinical Variables | Breast Cancer Patients (BC) | Healthy Controls (C) |
|---|---|---|
| Sample Size (n) | 18 | 9 |
| Age, y | ||
| Median | 57 | 41 |
| Range | 33–79 | 26–54 |
| Histology, % | ||
| In Situ ductal carcinoma | - | |
| Invasive ductal carcinoma | 83.3 | |
| Invasive lobular carcinoma | 5 | |
| Grading, % | ||
| Well differentiated (G1) | 5.5 | |
| Moderately differentiated (G2) | 22.2 | |
| Poor/undifferentiated (G3) | 50 | |
| Unknown | 11.1 | |
| Estrogen receptor status, % | ||
| Negative | 22.2 | |
| Positive (>1%) | 77.8 | |
| Progesterone receptor status, % | ||
| Negative | 33.3 | |
| Positive (>1%) | 66.7 | |
| HER2/Neu status, % | ||
| Negative | 88.8 | |
| Positive | 11.1 | |
| Ki-67, % | ||
| <14 | 11.1 | |
| ≥14 | 83.3 |
y, years; HER2/Neu, Human Epidermal Growth Factor 2.